Common myeloid progenitor cell (CMP)

Common myeloid progenitor cells (CMPs) are multipotent progenitor cells in the bone marrow that arise from hematopoietic stem cells and serve as precursors for several major blood lineages, including granulocytes (neutrophils, basophils, eosinophils), monocytes (eventually giving rise to macrophages and dendritic cells), erythrocytes, and megakaryocytes (platelet-producing cells)[1][3][5][7]. CMPs are distinguished from hematopoietic stem cells by their reduced self-renewal and more lineage-restricted differentiation potential. They play essential roles in blood cell replenishment, immune responses, and tissue repair. While myeloid progenitors themselves are not targeted by drugs, inappropriate expansion (as in leukemia) or dysregulation (as in myelodysplastic syndromes or cancer) is relevant in disease contexts[6]. They are characterized in research and clinical practice by certain cell surface markers (e.g., CD34+, c-Kit+, lineage-), but not as druggable entities or receptors[3][5].

Other names

Myeloid progenitorMyeloid progenitor cellCMPCFU-GEMM (Colony-forming unit–granulocyte, erythrocyte, monocyte, megakaryocyte)

Not a direct pharmacological target